Midway Pharmaceuticals

Midway Pharmaceuticals was a biotechnology company focused on developing therapies to protect and repair the mucosal barrier of the gastrointestinal tract. The company's core technology involved the use of block copolymers, such as Poloxamer 188, to stabilize cell membranes and prevent the translocation of toxins and pathogens. Their primary research targets included inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, as well as radiation-induced gastrointestinal injury. Founded based on research from the University of Chicago, Midway aimed to provide a non-immunosuppressive approach to treating chronic inflammatory conditions by reinforcing physical cellular barriers. The company is currently considered inactive, with no recent clinical or corporate updates.